Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Targeting the interleukin-6/Jak/stat pathway in human malignancies.

Sansone P, Bromberg J.

J Clin Oncol. 2012 Mar 20;30(9):1005-14. doi: 10.1200/JCO.2010.31.8907. Epub 2012 Feb 21. Review.

2.

Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Lai SY, Johnson FM.

Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Review.

PMID:
20471303
3.

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA.

Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. Review.

4.

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z.

Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. Review.

PMID:
17168672
5.

Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.

Vale K.

Future Med Chem. 2016;8(4):405-19. doi: 10.4155/fmc.16.4. Epub 2016 Mar 2. Review.

PMID:
26934038
6.

Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer.

Roxburgh CS, McMillan DC.

Transl Res. 2016 Jan;167(1):61-6. doi: 10.1016/j.trsl.2015.08.013. Epub 2015 Sep 16. Review.

PMID:
26432924
7.

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM.

Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9. Review. Erratum in: Drugs. 2017 May;77(8):939. Drugs. 2017 Jun 12;:.

PMID:
28255960
8.

Dynamics and non-canonical aspects of JAK/STAT signalling.

Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Müller-Newen G.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):524-32. doi: 10.1016/j.ejcb.2011.09.005. Epub 2011 Oct 21. Review.

PMID:
22018664
9.

Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Waldmann TA, Chen J.

Annu Rev Immunol. 2017 Apr 26;35:533-550. doi: 10.1146/annurev-immunol-110416-120628. Epub 2017 Feb 9. Review.

PMID:
28182501
10.

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L.

Cytokine. 2016 Nov;87:26-36. doi: 10.1016/j.cyto.2016.06.017. Epub 2016 Jun 24. Review.

PMID:
27349799
11.

Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.

Vafadari R, Weimar W, Baan CC.

Clin Chim Acta. 2012 Sep 8;413(17-18):1398-405. doi: 10.1016/j.cca.2011.12.023. Epub 2012 Jan 10. Review.

PMID:
22261016
12.
13.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, Salem M, Pedersen J, Nielsen OH.

Pharmacol Res. 2013 Oct;76:1-8. doi: 10.1016/j.phrs.2013.06.007. Epub 2013 Jul 2. Review.

PMID:
23827161
14.

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Springuel L, Renauld JC, Knoops L.

Haematologica. 2015 Oct;100(10):1240-53. doi: 10.3324/haematol.2015.132142. Review.

15.

Therapeutic targeting of the Jak/STAT pathway.

Aittomäki S, Pesu M.

Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):18-23. doi: 10.1111/bcpt.12164. Epub 2013 Nov 15. Review.

16.

Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.

Groner B, von Manstein V.

Mol Cell Endocrinol. 2017 Aug 15;451:1-14. doi: 10.1016/j.mce.2017.05.033. Epub 2017 May 30. Review.

PMID:
28576744
17.

The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

Wang SW, Sun YM.

Int J Oncol. 2014 Apr;44(4):1032-40. doi: 10.3892/ijo.2014.2259. Epub 2014 Jan 15. Review.

PMID:
24430672
18.

The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.

Cai B, Cai JP, Luo YL, Chen C, Zhang S.

Inflammation. 2015 Aug;38(4):1599-608. doi: 10.1007/s10753-015-0135-z. Review.

PMID:
25676437
19.

Mast cell homeostasis and the JAK-STAT pathway.

Morales JK, Falanga YT, Depcrynski A, Fernando J, Ryan JJ.

Genes Immun. 2010 Dec;11(8):599-608. doi: 10.1038/gene.2010.35. Epub 2010 Jun 10. Review.

20.

STAT3 inhibitors: finding a home in lymphoma and leukemia.

Munoz J, Dhillon N, Janku F, Watowich SS, Hong DS.

Oncologist. 2014 May;19(5):536-44. doi: 10.1634/theoncologist.2013-0407. Epub 2014 Apr 4. Review.

Supplemental Content

Support Center